摘要
目的采用荟萃分析的方法评估益生菌制品对人群血脂水平的影响。方法从Pub Med、Cochrane Library、Web of Science、EMBASE、中国期刊全文数据库、万方数据库、中文科技期刊全文数据库等数据库中检索关于应用益生菌制品对人群血脂水平进行干预的随机对照试验研究,利用Rev Man 5.3.3软件对纳入研究结果进行Meta分析。结果本研究共纳入18篇文献。Meta分析结果显示,与安慰剂组相比,益生菌干预组血清总胆固醇[均数差(mean difference,MD)=-0.2 mmol/L,95%可信区间(confidence intervals,CI):-0.28^-0.12 mmol/L]和低密度脂蛋白胆固醇(MD=-0.19 mmol/L,95%CI:-0.26^-0.13 mmol/L)下降更为明显(P<0.000 01),2组高密度脂蛋白胆固醇及甘油三酯比较差异无统计学意义(P>0.05)。高脂血症人群、体重指数在25~29.9 kg/m2的超重人群、干预期超过4周人群、接受肠道微生态制剂人群获益更大。结论益生菌制品可有效下调血脂异常及健康人群的血清总胆固醇及低密度脂蛋白胆固醇水平,有望应用于血脂异常患者的动脉粥样硬化性心血管疾病一级及二级预防。
Objective To evaluate the efficacy of probiotic products on human serum lipid profiles,we conducted a meta-analysis. Methods Randomized,controlled clinical trials relating to interventional studies of probiotic products on human serum lipid profiles were obtained by search of electronic databases,such as Pub Med,Cochrane Library,Web of Science,EMBASE,Chinses Periodical Full Text Database,Wanfang Database,Full Text Database of Chinese Sci-Tech Periodical.Statistical analysis was performed with Review Manager 5. 3. 3. Results Eighteen randomized controlled trials were analyzed in our study. Meta-analysis results showed that the serum total cholesterol [mean difference（ MD） =-0. 2 mmol/L,95% confidence intervals（ CI） ：-0. 28—-0. 12 mmol/L] and low-density lipoprotein cholesterol（ MD =-0. 19 mmol/L,95% CI：-0. 26 —-0. 13 mmol/L） were significantly decreased（ P 〈0. 000 01） in probiotic intervention group compared with the placebo group,while high-density lipoprotein cholesterol and triglyceride had no significant difference（ P 〉0. 05）. Patients with hyperlipidemia,overweight（ body weight index was 25—29. 9 kg/m2）,receiving long-term intervention duration（ 4 weeks） and intestinal micro-ecologic products got more benefit. Conclusion The probiotic products were effective in down-regulating the serum total cholesterol and low-density lipoprotein cholesterol levels in dyslipidemia patients and healthy individuals. It is expected to be used in the primary and secondary prevention of atherosclerotic cardiovascular diseases in patients with dyslipidemia.
作者
王力
朱智明
沈雅庭
刘彦波
方志荣
WANG Li;ZHU Zhiming;SHEN Yating;LIU Yanbo;FANG Zhirong(Department of Internal Medicine,The 413th Hospital of PLA,Zhoushan Zhejiang 316000,China;Department of Cardiology,Navy General Hospital,Beijing 100048,China)
出处
《转化医学杂志》
2018年第3期159-166,共8页
Translational Medicine Journal
关键词
高脂血症
益生菌
随机对照试验
META分析
Hyperlipidemias
Probiotics
Randomized controlled trials
Meta-analysis
